Patient-centric trials for therapeutic development in precision oncology

Andrew V. Biankin (), Steven Piantadosi and Simon J. Hollingsworth
Additional contact information
Andrew V. Biankin: Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow
Steven Piantadosi: Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Simon J. Hollingsworth: Innovative Medicines & Early Development Oncology, AstraZeneca, Cambridge Science Park

Nature, 2015, vol. 526, issue 7573, 361-370

Abstract: Abstract An enhanced understanding of the molecular pathology of disease gained from genomic studies is facilitating the development of treatments that target discrete molecular subclasses of tumours. Considerable associated challenges include how to advance and implement targeted drug-development strategies. Precision medicine centres on delivering the most appropriate therapy to a patient on the basis of clinical and molecular features of their disease. The development of therapeutic agents that target molecular mechanisms is driving innovation in clinical-trial strategies. Although progress has been made, modifications to existing core paradigms in oncology drug development will be required to realize fully the promise of precision medicine.

Date: 2015
References: Add references at CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.nature.com/articles/nature15819 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:526:y:2015:i:7573:d:10.1038_nature15819

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature15819

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().